See Anoro Ellipta’s head-to-head data
Anoro Ellipta is the only LAMA/LABA with head-to-head data vs. a LAMA²⁻⁵ and vs. two LAMA/LABAs.⁶ ⁷
Not a healthcare professional? Visit our Public site
Not a healthcare professional? Visit our Public site
has been added to your basket
59
This is a fictional patient for illustrative purposes.
Anoro Ellipta is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.1
He is a 62-year-old COPD patient being treated with a short-acting bronchodilator agonist therapy (SABA) as required, but is not yet on a maintenance therapy.
Symptoms:
Robert is starting to struggle with climbing stairs and doing household chores. He now watches television instead of going for long walks outside, or dancing with his wife.
Fictional patient for illustrative purposes
Adverse events should be reported. Reporting forms and information can be found at
https://yellowcard.mhra.gov.uk/ .
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.
© 2021 GSK group of companies or its licensor. ANORO was developed in collaboration with INNOVIVA.
Trademarks are owned by or licensed to the GSK group of companies.
PM-GB-UCV-WCNT-200034 May 2021